Idorsia Pharmaceuticals Ltd: Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - February 6, 2023 Idorsia Ltd (SIX: IDIA) today announces the initial findings of REACT, a Phase 3 study which investigated the

Related Keywords

Japan ,United States ,Allschwil ,Switzerland General ,Switzerland ,America ,Swiss ,Andrewc Weiss ,Jean Paul Clozel ,Schwierige Zeiten ,Idorsia Ltd ,Head Of Investor Relations Corporate Communications ,Idorsia Pharmaceuticals Ltd ,Swiss Exchange ,World Federation Of Neurological Societies ,Paul Clozel ,Chief Executive Officer ,World Federation ,Neurological Societies ,North America ,Lancet Neurology ,Vice President ,Investor Relations ,Pharmaceuticals Ltd ,Idorsia ,Pharmaceuticals ,Nnounces ,Results ,React ,Hase ,Study ,Clazosentan ,Patients ,Following ,Neurysmal ,Ubarachnoid ,Hemorrhage ,